In syngeneic human CD20- (hCD20-) expressing models of lymphoma, systemic administration of a TLR7 agonist (R848) reportedly augmented responses upon combinatorial administration with obinutuzumab, thus preventing tumor recurrence. The gene discussed is TLR7; the disease is lymphoma.